Orvanthe discovers, tests and makes its own medicines: 600 people, two programmes in the clinic and a sterile plant, explaining the science without the hype.
Programmes
Next OVT-114 · Interim safety review, Q3 2027
The plate
Every programme begins on a plastic plate with 96 small wells. This is the first experiment any molecule has to pass.
Illustrative data from a concept assay. A good curve is the start of a programme, not evidence that a medicine works.
Pipeline
Five programmes, ordered by how far they have travelled. A bar is filled only for work that is done.
Full pipeline and study designs| Programme | Target class | Area | Disc.Precl.Ph 1Ph 2Ph 3Phase | |
|---|---|---|---|---|
| OVT-114 Enrolling | Kinase inhibitor, oral small molecule | Fibrotic lung disease | Phase 2 Study OV-114-03 | |
|
Does a daily tablet slow the loss of lung function? Adults living with fibrotic lung disease take OVT-114 or a placebo once a day for a year. We measure how much breathing capacity each group loses, and which dose people tolerate. The study does not yet tell us whether it helps. That is the question it exists to answer. Next milestone Interim safety review, Q3 2027 |
||||
| OVT-207 Dosing | Enzyme stabiliser, oral small molecule | Rare metabolic disorders | Phase 1 Study OV-207-02 | |
|
Can a molecule hold a faulty enzyme in its working shape? Some rare metabolic disorders come from an enzyme that folds badly and is cleared before it can work. OVT-207 is designed to hold it in shape. Study OV-207-02 gives rising doses to small groups of volunteers to learn how the body handles it. Nobody is treated for the condition in this study. Next milestone Dose escalation complete, Q2 2027 |
||||
| OVT-319 Safety studies | Cytokine receptor antagonist, antibody | Inflammatory skin disease | Preclinical No study yet | |
|
Is it safe enough to give to a person for the first time? OVT-319 blocks one signal the skin uses to call in inflammation. Before anyone receives a first dose, it has to pass a set of safety and manufacturing studies that tell us what a cautious starting dose looks like. If any of them fails, it stops here. Next milestone Decision to enter the clinic, Q1 2028 |
||||
| OVT-402 Lead series | Matrix modulator, inhaled peptide | Fibrotic lung disease | Discovery No study yet | |
|
Could a second route into the same disease work better? OVT-114 acts inside the cell. OVT-402 is an earlier idea that acts on the scar tissue around it, breathed in rather than swallowed. We are choosing between three close relatives on the plate. Most ideas at this stage never become medicines, and we say so. Next milestone Candidate chosen, late 2027 |
||||
| OVT-515 Target validation | RNA-targeting small molecule | Rare metabolic disorders | Discovery No study yet | |
|
Is the target the right one? The newest programme asks a question before it asks for a molecule: if we lower this one message in the cell, does the disease process slow in our models? Until the answer is yes in two labs, no chemistry starts. Next milestone First screen read, mid 2027 |
||||
Concept company: no real medicines. Phases follow the usual sequence of drug development. Dates are plans, not promises.
Notebook, p. 112How we work
Three entries from a working week. Every step in the building is recorded before it is trusted.
Second gloves over the cuffs. Nothing enters the filling room that has not been wiped twice and logged once.
Six candidate mixtures, seven days on the bench. Clear at day 7 counts. Cloudy at day 7 is written up, not thrown away.
Steam in place, 121 °C for 30 minutes, then a swab from the same eleven points as last time. Same points, every time.
Made here
Our sterile plant fills the vials used in our own studies. Choose a stage to see how clean the air is around it.
Choose a stage
Clean grade Grade C
Empty glass vials are rinsed inside and out with purified water and clean air before anything else touches them.
Clean grade Grade C to A
A hot-air tunnel takes the vials above 300 °C, which destroys any trace of bacteria, then cools them into the protected zone.
Clean grade Grade A in B
Needles dose each vial to the microlitre under a constant downward flow of filtered air. People never reach into this zone.
Clean grade Grade A in B
Some medicines keep better as a powder. The freeze dryer removes the water slowly over two days, then the stoppers are pressed home.
Clean grade Grade D
Cameras and a trained inspector check every sealed vial against light and dark backgrounds. Anything in doubt is set aside.
Careers
Four of the roles open now. The rest, and an honest account of a day in the lab, are on the careers page.
Partner and investor desk
Answered within five working days
01 Business development
We license programmes out at the right stage, take promising work in, and fill clinical batches for partners in our plant.
02 Investors
Results are published on the day, in full, with the slides. A concept calendar:
03 Clinicians
Our clinical team answers questions from doctors and study nurses about who may take part in Study OV-114-03 and Study OV-207-02.
Looking for a job instead? Careers